CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals (AMEX: JAV) announced that 3 patients began treatment yesterday in the second of two planned Phase 3 clinical studies for its injectable NSAID, Dyloject™ (injectable diclofenac sodium). This US study will enroll patients with moderate-to-severe postoperative pain following elective orthopedic surgery. Patient enrollment was recently completed in the first pivotal Phase 3 study, and an announcement of top-line results is expected by year end. This first study focused on postoperative pain after elective abdominal surgery.
